Antibody drug conjugates (adc) that bind to 161p2f10b proteins

Abstract

Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

1 . (canceled) 
     
     
         2 . An antibody drug conjugate comprising an antibody or antigen binding fragment thereof which binds to a 161P2F10B protein variant of SEQ ID NO:2, wherein the antibody or antigen binding fragment thereof is conjugated to 1 to 12 units of monomethyl auristatin F (MMAF), each unit of MMAF being conjugated via a linker, and wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 142 of SEQ ID NO: 7 and a light chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 127 of SEQ ID NO: 8. 
     
     
         3 . A method of delivering a cytotoxic agent or a diagnostic agent to a cell, comprising:
 providing MMAF(s) conjugated to an antibody or fragment thereof that binds specifically to a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 142 of SEQ ID NO: 7 and a light chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 127 of SEQ ID NO: 8, to form an antibody drug or fragment drug conjugate; and   exposing the cell to the antibody drug or fragment drug conjugate.   
     
     
         4 . A method of inhibiting growth of cancer cells in a subject, comprising:
 administering to said subject an antibody drug conjugate, wherein the antibody drug conjugate comprises an antibody or antigen binding fragment thereof which binds to a 161P2F10B protein variant of SEQ ID NO:2, wherein the antibody or antigen binding fragment thereof is conjugated to 1 to 12 units of monomethyl auristatin F (MMAF), each unit of MMAF being conjugated via a linker, and wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 142 of SEQ ID NO: 7 and a light chain variable region consisting of the amino acid sequence ranging from residue 20 to residue 127 of SEQ ID NO: 8.